Ikena Oncology Inc
NASDAQ:IKNA 11:50:28 AM EDT
| Market Cap (Intraday) | 82.50M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $11.57 |
| 50-Day MA | $12.37 |
| 200-Day MA | N/A |
Ikena Oncology Inc Stock, NASDAQ:IKNA
645 Summer Street, Suite 101, Boston, Massachusetts 02210
United States of America
Phone: +1.857.273.8343
Number of Employees: 33
Description
Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.